A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate

Clinical and Experimental Rheumatology

Volumn 30, Issue 2, 2012, Pages 156-163

  Hobl, Eva Luise ^a   Jilma, Bernd ^a   Erlacher, Ludwig ^b   Duhm, Bernhard ^b   Mustak, Monika ^b   Bröll, Hans ^c   Högger, Petra ^d   Rizovski, Blanka ^a   Mader, Robert M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c Ludwig Boltzmann Cluster for Rheumatology   (Austria)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Methotrexate; Methotrexate polyglutamates; Outcome; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; METHOTREXATE POLYGLUTAMATE 1; METHOTREXATE POLYGLUTAMATE 2; METHOTREXATE POLYGLUTAMATE 3; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BASOPHIL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ACTIVITY SCORE IN 28 JOINTS; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG RESPONSE; EOSINOPHIL; ERYTHROCYTE SEDIMENTATION RATE; EVALUATOR GLOBAL ASSESSMENT; FATIGUE; FEMALE; FLUOROMETRY; HEALTH ASSESSMENT QUESTIONNAIRE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; JOINT SWELLING; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING STIFFNESS; NAUSEA; PATIENT GLOBAL ASSESSMENT; PHOTOOXIDATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRIA; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG MONITORING; ERYTHROCYTES; FEMALE; FLUOROMETRY; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POLYGLUTAMIC ACID; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84863751959     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. KAPRAL T, STAMM T, MACHOLD KP, MONTAG K, SMOLEN JS, ALETAHA D: Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. Arthritis Res Ther 2006; 8: R46.
2. VAN DER HEIJDEN JW, DIJKMANS BA, SCHEPER RJ, JANSEN G: Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nat Clin Pract Rheumatol 2007; 3: 26-34.
3. WEINBLATT ME, COBLYN JS, FOX DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
4. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S179-185.
5. RAU R, HERBORN G: Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S83-94.
6. PINCUS T, FERRACCIOLI G, SOKKA T et al.: Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002; 41: 1346-56.
7. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-50.
8. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
9. BANNWARTH B, PEHOURCQ F, SCHAEVERBEKE T, DEHAIS J: Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194-210.
10. GALIVAN J: Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 1980; 17: 105-10.
11. VAN EDE AE, LAAN RF, BLOM HJ, DE ABREU RA, VAN DE PUTTE LB: Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27: 277-92.
12. SZETO DW, YUNG-CHI C, ROSOWSKY A et al.: Human thymidylate synthetase-III: Effects of methotrexate and folate analogs. Biochemical Pharmacology 1979; 28: 2633-7.
13. DERVIEUX T, ORENTAS LEIN D, MARCELLETTI J et al.: HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003; 49: 1632-41.
14. ANGELIS-STOFORIDIS P, VAJDA FJ, CHRISTOPHIDIS N: Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: 313-20.
15. ALBRECHT K, MULLER-LADNER U: Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S95-101.
16. BRAUN J: Optimal administration and dosage of methotrexate. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S46-51.
17. YAZICI Y: Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S65-67.
18. GOODMAN S: Measuring methotrexate polyglutamates. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S24-26.
19. STAMP LK, O'DONNELL JL, CHAPMAN PT et al.: Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010; 62: 359-68.
20. HERMAN RA, VENG-PEDERSEN P, HOFFMAN J, KOEHNKE R, FURST DE: Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989; 78: 165-71.
21. DALRYMPLE JM, STAMP LK, O'DONNELL JL, CHAPMAN PT, ZHANG M, BARCLAY ML: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299-308.
22. SCHWARTZ JI, AGRAWAL NG, WONG PH et al.: Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J Clin Pharmacol 2001; 41: 1120-30.
23. DAWES PT, SMITH DH, SCOTT DL: Massive eosinophilia in rheumatoid arthritis: report of four cases. Clin Rheumatol 1986; 5: 62-5.
24. HALLGREN R, FELTELIUS N, SVENSON K, VENGE P: Eosinophil involvement in rheumatoid arthritis as reflected by elevated serum levels of eosinophil cationic protein. Clin Exp Immunol 1985; 59: 539-46.
25. ATHREYA BH, MOSER G, RAGHAVAN TE: Increased circulating basophils in juvenile rheumatoid arthritis. A preliminary report. Am J Dis Child 1975; 129: 935-7.